Effect of verapamil on ischemia and ventricular arrhythmias after an acute myocardial infarction: Prognostic implications

This article is a review of presented subsets of the Danish Verapamil Infarction Trial II (DAVIT II) regarding the effect of verapamil on postinfarction ischemia, ventricular arrhythmias, and heart rate (HR), and the prognostic implications of these findings. Patients underwent Holter monitoring for 24-48 h at I week. i.e., before randomization to long-term treatment with placebo or verapamil, and after 1 month and about 1 year of study treatment. Ischemia: 18% of the patients had transient ST-segment deviation before randomization: 24% of the placebo-and 8% of the verapamiltreated patients (p = 0.04) showed ischemia after 1 month: and after 1 year. the figures were 26 and 4%. respectively (p = 0.02). The 18-month major event rate. i.e., first reinfarction or death, in patients with ischemia before randomization were 40 and 23.8% in patients without ischemia (p = 0.06). Arrhythmias: In the placebo group the prevalence and incidence of many ventricular ectopic beats (VEBs). i.e., more than 10 VEBs/h. increased significantly during the first years after infarction: this was not the case in the verapamil patients group. The mean HR was significantly reduced by yerapamil treatment after 1 month and after 16 months of treatment. Multivariate analysis demonstrated the presnce of treatment. Multivariate analysis demonstrated the presence of more than 10 VEBs/h only early (i.e., 1 week) but not late (i.e., 1 month) after infarction. to be an independent predictor of major events during 18 months’ follow-up observation. A HR above 80 beats/min independently predicted major events when appearing both early and late after infarction. The anti-ischemic effect of verapamil. documented by a significant reduction of transient ischemic episodes and indicated by a significant reduction of 24-h mean HR, may explain the reduction of major events in the verapamil-treated patients compared to those given placebo in the DAVIT II study.